100 Recruiting Studies Using Daratumumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Daratumumab
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
📍 Stanford University School of Med /ID# 242809 — Stanford, California
Relapsed/Refractory Multiple Myeloma
View Study & Checklist ➔Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
Multiple Myeloma
View Study & Checklist ➔Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
📍 Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
Multiple Myeloma
View Study & Checklist ➔A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Multiple Myeloma
View Study & Checklist ➔A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Univ of Colorado Cancer Center /ID# 167331 — Aurora, Colorado
Multiple Myeloma
View Study & Checklist ➔Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM
📍 Northern Light Eastern Maine Medical Center — Bangor, Maine
Myeloma, Multiple
View Study & Checklist ➔A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
📍 Weill Cornell Medicine - Multiple Myeloma Center — New York, New York
Multiple Myeloma
View Study & Checklist ➔COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
📍 Boston Medical Center — Boston, Massachusetts
AL Amyloidosis
View Study & Checklist ➔Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
📍 West Virginia University Cancer Institute Mary Babb Randolph Cancer Center — Morgantown, West Virginia
Glioblastoma
View Study & Checklist ➔A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
📍 Local Institution - 119 — Denver, Colorado
Multiple Myeloma
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
📍 University of Arkansas for Medical Sciences /ID# 243096 — Little Rock, Arkansas
Relapsed/Refractory Multiple Myeloma
View Study & Checklist ➔A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
Multiple Myeloma
View Study & Checklist ➔A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Multiple Myeloma
View Study & Checklist ➔Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
📍 M D Anderson Cancer Center — Houston, Texas
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
📍 City of Hope — Duarte, California
Amyloidosis
View Study & Checklist ➔Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
📍 Arizona Oncology Associates, PC - HOPE — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma
📍 The University of Chicago — Chicago, Illinois
Myeloma
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
📍 University of Alabama Comprehensive Cancer Center — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM
📍 Icahn School of Medicine at Mount Sinai — New York, New York
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔DARA RVD For High Risk SMM
📍 Stamford Hospital — Stamford, Connecticut
High-risk Smoldering Multiple Myeloma
View Study & Checklist ➔Daratumumab to Treat Active Lupus Nephritis
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Lupus Nephritis
View Study & Checklist ➔Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant
📍 Moffitt Cancer Center — Tampa, Florida
Smoldering Multiple Myeloma
View Study & Checklist ➔A Study of Daratumumab
📍 University of Miami Sylvester Cancer Center — Miami, Florida
Multiple Myeloma
View Study & Checklist ➔Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
ISS Stage III Plasma Cell Myeloma
View Study & Checklist ➔Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma
📍 UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
Multiple Myeloma
View Study & Checklist ➔Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma
📍 University of Rochester Medical Center — Rochester, New York
Multiple Myeloma
View Study & Checklist ➔A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
📍 University Of California San Diego — San Diego, California
Multiple Myeloma
View Study & Checklist ➔A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
📍 The University of Arizona Cancer Center — Tucson, Arizona
Multiple Myeloma
View Study & Checklist ➔MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Multiple Myeloma
View Study & Checklist ➔A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
📍 City of Hope — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
📍 University of Miami — Miami, Florida
Multiple Myeloma
View Study & Checklist ➔Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
📍 Pacific Cancer Care — Monterey, California
Monoclonal Gammopathy
View Study & Checklist ➔Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
📍 Hackensack University Medical Center — Hackensack, New Jersey
Recurrent Plasma Cell Myeloma
View Study & Checklist ➔Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure
📍 Alaska Oncology and Hematology LLC — Anchorage, Alaska
Myeloma Multiple
View Study & Checklist ➔Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Multiple Myeloma
View Study & Checklist ➔A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
📍 University of Arkansas — Little Rock, Arkansas
Multiple Myeloma
View Study & Checklist ➔Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Yuma, Arizona
Multiple Myeloma
View Study & Checklist ➔Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
📍 Stanford University — Palo Alto, California
Amyloid
View Study & Checklist ➔Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
📍 University of Colorado Hospital — Aurora, Colorado
Multiple Myeloma in Relapse
View Study & Checklist ➔Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma
📍 City of Hope Medical Center — Duarte, California
Plasma Cell Myeloma
View Study & Checklist ➔A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Plasma Cell Myeloma
View Study & Checklist ➔A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
📍 University of Alabama Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
📍 Local Institution - 035 — Hot Springs, Arkansas
Multiple Myeloma
View Study & Checklist ➔A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
📍 Local Institution - 102 — Scottsdale, Arizona
Multiple Myeloma
View Study & Checklist ➔A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
📍 University of Arizona Cancer Center /ID# 285339 — Tucson, Arizona
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma
📍 Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Relapse Multiple Myeloma
View Study & Checklist ➔ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)
📍 University of Miami — Miami, Florida
Multiple Myeloma
View Study & Checklist ➔A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Relapsed and/or Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
📍 City of Hope National Medical Center /ID# 273132 — Duarte, California
Multiple Myeloma
View Study & Checklist ➔Teclistamab-Daratumumab in AL Amyloidosis
📍 Boston Medical Center — Boston, Massachusetts
Amyloid Light-chain Amyloidosis
View Study & Checklist ➔Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing
📍 Vanderbilt University Medical Center — Nashville, Tennessee
Multiple Myeloma
View Study & Checklist ➔A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
📍 University of Alabama At Birmingham Hospital — Birmingham, Alabama
Relapsed/Refractory Multiple Myeloma
View Study & Checklist ➔Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
📍 Children's National Hospital — Washington D.C., District of Columbia
Sickle Cell Disease
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
📍 University of Alabama at Birmingham — Birmingham, Alabama
Relapsed or Refractory Multiple Myeloma (RRMM)
View Study & Checklist ➔A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
📍 Jupiter Medical Center/Anderson Family Cancer Institute — Jupiter, Florida
Multiple Myeloma
View Study & Checklist ➔Pan Tumor Rollover Study
📍 Local Institution - 0220 — Huntsville, Alabama
Cancer
View Study & Checklist ➔A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
📍 University of Miami Miller School of Medicine — Miami, Florida
Plasmablastic Lymphoma
View Study & Checklist ➔A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
📍 Research Site — Duarte, California
Relapsed or Refractory Multiple Myeloma
View Study & Checklist ➔Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
📍 Mayo Clinic in Arizona — Scottsdale, Arizona
AL Amyloidosis
View Study & Checklist ➔A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
📍 University of Southern California /ID# 272414 — Los Angeles, California
Multiple Myeloma
View Study & Checklist ➔Selinexor and Backbone Treatments of Multiple Myeloma Patients
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
Multiple Myeloma
View Study & Checklist ➔Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Plasma Cell Myeloma
View Study & Checklist ➔Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
📍 Research Site — Gilbert, Arizona
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
📍 Mayo Clinic Hospital Scottsdale /ID# 278349 — Scottsdale, Arizona
Multiple Myeloma
View Study & Checklist ➔Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
📍 Emory Winship Cancer Institute — Atlanta, Georgia
Haematological Malignancy
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
📍 City of Hope — Duarte, California
Multiple Myeloma
View Study & Checklist ➔A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
📍 Colorado Blood Cancer Institute — Denver, Colorado
Multiple Myeloma
View Study & Checklist ➔IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
📍 Valkyrie Clinical Trials — Los Angeles, California
NHL
View Study & Checklist ➔Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Recurrent Multiple Myeloma
View Study & Checklist ➔Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
📍 City of Hope National Medical Center — Duarte, California
Multiple Myeloma
View Study & Checklist ➔Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
📍 Cross Cancer Institute — Edmonton, Alberta
Multiple Myeloma
View Study & Checklist ➔Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Smoldering Plasma Cell Myeloma
View Study & Checklist ➔Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma, Newly Diagnosed
View Study & Checklist ➔A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
📍 Research Site — Gilbert, Arizona
Relapsed Refractory Multiple Myeloma
View Study & Checklist ➔Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
📍 University of Miami — Miami, Florida
Refractory Multiple Myeloma
View Study & Checklist ➔A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
📍 Clovis Community Medical Center — Clovis, California
Multiple Myeloma
View Study & Checklist ➔Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
📍 Icahn School of Medicine at Mount Sinai — New York, New York
Multiple Myeloma in Relapse
View Study & Checklist ➔A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
📍 Scripps Clinic Torrey Pines — La Jolla, California
Multiple Myeloma
View Study & Checklist ➔Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
📍 Georgia Cancer Center-Augusta University — Augusta, Georgia
Multiple Myeloma
View Study & Checklist ➔A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
📍 Tufts Medical Center (Data Collection Only) — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
📍 Alliance for Clinical Trials in Oncology — Chicago, Illinois
Plasma Cell Leukemia
View Study & Checklist ➔Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
📍 City of Hope Medical Center — Duarte, California
Acute Lymphoblastic Leukemia
View Study & Checklist ➔Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
📍 Phoenix Children's Hospital — Phoeniz, Arizona
T-cell Acute Lymphoblastic Leukemia
View Study & Checklist ➔Daratumumab in Primary Antiphospholipid Syndrome
📍 Johns Hopkins University — Baltimore, Maryland
Autoimmune Disorders
View Study & Checklist ➔A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
📍 Emory University - Winship Cancer Institute — Atlanta, Georgia
High Risk Smoldering Multiple Myeloma (HR-SMM)
View Study & Checklist ➔Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
📍 Karmanos Cancer Institute — Detroit, Michigan
Multiple Myeloma
View Study & Checklist ➔Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell Disorders
📍 University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
Plasma Cell Disorder
View Study & Checklist ➔Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Lymphoma, Primary Effusion
View Study & Checklist ➔Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
📍 Mayo Clinic — Jacksonville, Florida
Proliferative Glomerulonephritis With Monoclonal IgG Deposits
View Study & Checklist ➔